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Summary
Objective
ANGPTL4 inhibits lipoprotein lipase in adipose tissue, regulating plasma triglycerides
levels. In persons with obesity plasma ANGPTL4 levels have been positively correlated
with body fat mass, TG levels and low HDL. A loss-of-function E40K mutation in
ANGPTL4 prevents LPL inhibition, resulting in lower TGs and higher HDLc in the general
population. Since obesity determines metabolic alterations and consequently is a major
risk factor for cardiovascular disease, the aim was to explore if obesity-related metabolic
abnormalities are modified by the ANGPTL4-E40K mutation.
Methods
ANGPTL4-E40K was screened in 1206 Italian participants, of which 863 (71.5%) with
obesity. All subjects without diabetes underwent OGTT with calculation of indices of
insulin-sensitivity.
Results
Participants with obesity carrying the E40K variant had significantly lower TG (p = 0.001)
and higher HDLc levels (p = 0.024). Also in the whole population low TGs and high HDLc
were confirmed in E40K carriers. In the obese subpopulation it was observed that almost
all E40K carriers were within the lowest quartile of TGs (p = 1.1 × 109). E40K had no sub-
stantial effect of on glucose metabolism. Finally, none of the obese E40K carriers had
T2D, and together with the favourable lipid profile, they resemble a metabolically healthy
obese (MHO) phenotype, compared to 38% of E40E wild-type obese that had diabetes
and/or dyslipidaemia (p = 0.0106).
Conclusions
In participants with obesity the ANGPTL4-E40K variant protects against dyslipidemia.
The phenotype of obese E40K carriers is that of a patient with obesity without metabolic
alterations, similar to the phenotype described as metabolic healthy obesity.
Keywords: Genetics, lipoprotein lipase, metabolic healthy obesity (MHO),
triglycerides.
Introduction
ANGPTL4 is a glycosylated secreted protein of the
Angiopoietin-like family that has emerged as a likely risk
factor and a possible target for the treatment of metabolic
alterations, including hypertriglyceridemia, glucose intol-
erance and dyslipidemia-related atherosclerotic cardio-
vascular disease (1–3). ANGPTL 3, 4 and 8 are
regulators of plasma triglycerides levels. ANGPTL4, in
particular, plays a key role in regulating lipid metabolism
related to the fasting/feeding states, in concert with
ANGPTL 3 and 8 (4).
With regards to obesity, plasma ANGPTL4 levels have
been positively correlated with body fat mass. Previous
studies have shown that ANGPTL4 circulating levels are
higher in patients with obesity, and correlate positively
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with triglyceride (TG) levels and negatively with High-
Density Lipoprotein cholesterol (HDLc) (1).
The ANGPTL4 protein is secreted mainly by liver
and adipose tissue in response to fasting or hypoxia.
One of its functions is inhibiting the lipolytic activity
of Lipoprotein Lipase (LPL) in adipose tissue (AT);
LPL “extracts” free fatty acids (FFA) from
Triglycerides-rich circulating lipoprotein (TRLs), both
chylomicrons (CM) and Very Low-Density Lipoproteins
(VLDLs), thus facilitating the route towards target tis-
sues such as adipose or muscle, modulating the stor-
age and oxidation of lipids (5). The net effect of
ANGPTL4 is therefore to maintain adequate TG and HDLc
levels in plasma during the fasting/feeding states. The
synthetized form of ANGPTL4 is 50-kD protein that needs
oligomerization for a proper secretion. Circulating pro-
teins are inactive as long as they are cleaved into 37-kD
C-terminal and 15-kD N-terminal fragments. C-terminal
fragments dissociate into monomers while N-terminal
rests in oligomers. These latter oligomers are necessary
and sufficient for LPL inhibition (6). Inhibition is accom-
plished through the conversion of LPL from active dimers
into inactive monomers (7). It is thought that ANGPTL4
can act both as a paracrine factor regulating LPL activity
in other tissue as well as an autocrine factor inhibiting
LPL activity in the tissue of its origin. Other recognized
functions are related to endothelial cell function, vascular-
ization and atherosclerosis. In mice studies, reducing
levels of ANGPTL4 improves glucose tolerance coupled
with increase in fat mass (8).
A missense mutation in ANGPTL4, the E40K
(rs116843064), resulted strongly associated with low
TGs and higher HDLc levels in plasma in different popula-
tions (9,10). Because it is an inhibiting protein, loss-of-
function (LoF) variants in ANGPTL4 such as E40K, act
by enhancing adipose-specific LPL activity, resulting in
lowering circulating TGs, a condition per se protective
against cardiovascular disease (CVD) (11). The associa-
tion of ANGPTL4 E40K mutation and CVD is still contro-
versial, but of note 4 out 5 of the larger studies revealed
a protective effect (odd ratio from 0.56 (for homozygotes)
- 0.86) (12–16). While LoF variants inactivating ANGPTL4
are likely protective on CVD risk (3), no other variants in
the same gene have been consistently associated with
CVD risk so far.
Since obesity is a major risk factor for CVD, and in view
of the impairment in metabolism and insulin regulation
that are a consequence of obesity, the aim of this study
was to explore if there is any interaction between the
E40K variant and obesity. In particular if obesity-related
metabolic alterations (i.e dyslipidemia, disglycaemia) are
modified by the presence of the variant. To our knowl-
edge, this interaction has not been explored before. Thus,
the presence of the E40K variant was examined in a very
well characterized adult obese population from Italy,
evaluating lipid profile, insulin regulation and metabolic
indices. The hypothesis is therefore that carriers of
ANGPTL4 E40K variant may be protected from obesity-
related dyslipidemia and/or other metabolic alteration,
resembling the metabolic healthy obesity phenotype.
Methods
For this study, 1206 participants were selected, of which
863 (71.5%) with obesity, among patients attending the
Internal Medicine outpatient clinics of Sapienza University
of Rome and the Metabolic and Diabetes Unit of the
Department of Experimental Medicine, Sapienza
University of Rome. All participants without a previous
diagnosis of diabetes underwent a standard 75 g oral
glucose tolerance test (OGTT) with measurements of
glucose and insulin at baseline and after 30, 60, 90, and
120 minutes. Patients were classified according to the
ADA 2018 diagnostic criteria in normal glucose tolerant
(NGT), with impaired fasting glucose (IFG), impaired
glucose tolerance (IGT) and affected by type 2 diabetes
T2D (17). All patients have undergone a structured
interview in order to collect information on family history
of diabetes and cardiovascular disease and on current
treatments. All participants had a complete work-up
including clinical examination, anthropometric measure-
ments, and laboratory tests. The diagnosis of hyperten-
sion was based on the presence of elevated systolic
(≥140 mmHg) and/or diastolic (≥90 mmHg) blood pres-
sure, and/or the current use of antihypertensive medica-
tions. Patients were classified as obese if measured BMI
was ≥30 kg/m2.
Laboratory measurements
The study cohort underwent fasting blood sampling to
assess FBG, glycosylated haemoglobin (HbAc1), total
cholesterol (TC), HDLc, TG, aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) by standard
laboratory methods. Insulin (Ins) was measured by radio-
immunoassay (ADVIA Insulin Ready Pack 100, Bayer
Diagnostics, Milan, Italy), with intra- and inter-assay coef-
ficients of variation <5%. Low-density lipoprotein (LDL)
cholesterol value was obtained using the Friedewald
formula.
Surrogate indices of insulin resistance and secretion,
i.e. HOMA-IR for insulin resistance, HOMA-B for insulin
secretion and insulin sensitivity index (ISI) were calculated
as previously described by Matthews et al. (18) and
Matsuda et al. (19).
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Genotyping assay
The E40K variant in ANGPTL4 gene was assayed using
the TaqMan assay ID C_156222000_10 (Applied
Biosystems, Foster City, CA USA), in a total volume of
10 μl on an EcoTM RealTime PCR System by Illumina
(San Diego, CA, USA). The plate was run at 95°C for
10 minutes, 95°C for 15 seconds, and 60°C for 1 minute
for 50 cycles. Positive and negative controls are included
in each experiment to asses genotyping quality, which in-
clude beside two blank wells, two known heterozygotes
and wild-types samples. The genotype concordance
was higher than 99%. Allele frequency was in Hardy
Weinberg Equilibrium.
Statistical analysis
All statistical analyses were performed with SPSS 24.0
statistical package. Categorical variable distribution was
compared by χ2 and T-Student tests. To test for the ef-
fects of genotypes on the median of the quantitative
traits, a linear regression analysis was performed (under
the additive model) and the results were adjusted for the
relevant covariates, including gender, age, and BMI.
Normality was checked using Kolmogorov-Smirnof.
Skewed variables were logarithmically transformed be-
fore the analyses or assessed using non-parametric test
such as Mann–Whitney.
Power analysis was performed by the Genetic Associ-
ation Study (GAS) Power Calculator (Johnson JL, Univer-
sity of Michigan 2017) (20) commonly used to compute
statistical power for one-stage genetic association stud-
ies. Lipid levels variance in this population was estimated
as 0.30. Assuming an allele frequency of 0.02 and an ad-
ditive model for disease risk, with a sample size of 1200
the expected power under a significance level of 0.05
was >80% to identify an OR equal or superior than 1.65.
This study was reviewed and approved by the Ethical
Committee of Policlinico Umberto I, Sapienza University
of Rome, and conducted in conformance with the Helsinki
Declaration. Written consent was obtained from all partic-
ipants before the study.
Results
Anthropometric and clinical characteristics of study pop-
ulation are summarized in Table 1, where the entire popu-
lation is shown on the left side and, on the right, it is
Table 1 Clinical characteristics of Italian population (n = 1206) stratified for E40K ANGPTL4 variant
n = 1206
Whole population E40E E40K
p-valueMedian (25–75)% Median (25–75)% Median (25–75)%
Sex M/F (%) 552/654 (46/54) - 542/641 (46/54) - 10/13 (43/57) - -
Age (yrs) 51 (38–62) 52 (38–62) 45 (30–62) 0.199
BMI (kg/m2) 35.4 (29–43) 35.2 (29–43) 39 (32.5–45) 0.079
G0’ (mg/dl) 95 (84–113) 95 (84–114) 9 (81–108) 0.375
G1200 (mg/dl) 122 (100–150) 122 (100–150) 111 (98–144) 0.406
INS0’ (μU/mL) 22.1 (14.7–33.7) 21.8 (14.5–33.6) 27.7 (18–44.3) 0.142
INS1200 (μU/mL) 106.8 (55.7–189.3) 106.4 (55–187.4) 112.7 (66.8–200) 0.534
Col Tot (mg/dl) 194.8 (168.1–224.8) 194.5 (168.1–224) 199.4 (167.3–235) 0.456
HDLc (mg/dl) 46 (38.7–54.9) 46 (38.6–54.7) 47.8 (42.9–65.5) 0.087
TG (mg/dl) 118.3 (84.2–171.7) 120 (85–173) 83 (57.1–118) 0.001
LDLc (mg/dl) 120.7 (96–145.8) 120.2 (95.8–145.6) 133.9 (107–156) 0.174
AST (U/L) 20 (15–25) 20 (15–25) 19.5 (17–22) 0.762
ALT (U/L) 28.1 (20–42.8) 28.1 (20–43) 26.6 (21.5–38.5) 0.840
PAS (mmHg) 130 (120–140) 130 (120–140) 130 (120–140) 0.357
PAD (mmHg) 80 (80–90) 80 (80–90) 85 (70–90) 0.634
HOMA-IR 5.6 (3.5–9.4) 5.5 (3.5–9.4) 7.1 (4.5–11.7) 0.434
HOMA-B 295.6 (183.7–466.1) 293.5 (180.8–464.7) 391.6 (232.8–497.8) 0.227
ISI 2.1 (1.3–3.3) 2.1 (1.3–3.3) 2.1 (1.1–2.7) 0.316
Data are expressed as median (25th–75th) percentile range, unless for gender expressed as count (Male/Female) and percentage. P-value are
calculated by Mann–Whitney.
BMI: Body Mass Index; G0’: Fasting glucose from OGTT; G120’: blood glucose at 1200 after OGTT; INS0’: Fasting Insulin from OGTT; INS120’:
Circulating Insulin at 1200 after OGTT; Col Tot: Total Cholesterol; HDLc: High Density Lipoprotein cholesterol; TG: Triglycerides; LDLc: Low Den-
sity lipoprotein cholesterol; AST: aspartate transaminase; ALT: alanine transaminase; PAS: Pulmonary Artery Pressure Systolic; PAD: Pulmonary
Artery Pressure Diastolic; HOMA-IR: homeostatic model assessment of insulin resistance; HOMA-B: homeostatic model assessment of beta-
cell function; ISI: Matsuda Insulin Sensitive Index.
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stratified according to E40K variant. As expected the en-
tire population shows a high median BMI and impaired in-
dices of insulin resistance and secretion, due to the high
prevalence of patients with obesity, together with normal
levels of all the other parameters. As previously reported,
carriers of E40K show highly significant lower TG levels
(p = 0.001), while all the other lipid parameters show
non-significant differences. Interestingly, we observed a
minor allele frequency (MAF) of 1.9%, in this Italian popu-
lation, rarer than in other European populations (5%) (21).
Linear logistic regression in the whole population
showed significant associations between E40K variant
and TG and HDLc levels, as show in Table 2a. These as-
sociations stand to the adjustment for established con-
founding factor (such as age, sex and BMI), and result in
a similar effect size but on the opposite direction, as ex-
pected for the TG - HDLc relation (Table 2b).
Then, the obese sub-population (n = 863) was exam-
ined. The clinical characteristics of this sub-population
are summarized in Table 3, where a typical metabolic pro-
file of such kind of patients is observed (high BMI, high
mean fasting glucose, high HOMA-IR and low ISI).
The association of E40K with lower TG-level was also
confirmed in this obese sub-population (p = 0.001). Also
the association with higher HDLc plasma levels in carriers
(p = 0.024) was confirmed (Figure 1). Despites some indi-
cations from previous studies (2,3,9,16) on a possible
modulation of circulating insulin levels, no difference in
glucose nor insulin curves derived from the OGTT in car-
riers versus non-carriers was found (data not shown).
When participants with a normal lipid profile (i.e.
TGs ≤ 150 mg/dL and HDLc ≥40 or ≥ 50 mg/dL in men
or women, respectively) were selected within the obese
sub-population, the frequency of these patients was
around 75% in E40K carriers compared to only 25% in
E40E participants (p = 0.02) (Figure 2), confirming that
E40K carriers are indeed more metabolically healthy.
As a further demonstration of the metabolically health-
ier effects of E40K, in the whole cohort the frequency of
E40K carriers resulted significantly higher in the lower
quartile of TGs compared to the highest quartile of TGs
(p = 0.017) (Figure 3). Contrariwise, the number of E40K
carriers was higher in the upper quartile of distribution of
the BMI (Figure 3).
In the obese sub-population, E40K carriers were al-
most all within the lower quartile of TGs (p = 1.1 × 109),
but as expected, no difference was observed in BMI quar-
tiles, due to sub-population selection (all with obesity)
(Figure 3).
Finally, looking at participants in the lower quartile of
TGs, there was a more than 6-fold probability to find the
E40K variant than in patients in the 75°, with an Odds Ra-
tio (OR) of 6.208 [1.377–27.978; p = 0.017]. This associa-
tion resisted to adjustment for recognized risk factors
such as age, sex and BMI (OR = 6.225 [1.317–29.413]
p = 0.021). In the obese subgroup the probability of
E40K carriers of being in the 25° percentile of TGs was
5.6-fold (p = 0.026), and after adjustment for sex and
age was almost 6 (OR = 5.9; p = 0.027).
Regarding BMI, binary logistic regression analysis
showed that patients in the upper quartile of BMI had a
8-fold probability to be E40K carriers than those in the
lower quartile (OR = 8.027 [0.998–64.577] p = 0.050). Ad-
justment for established risk factors increased the signif-
icance and the probability associated to the upper
quartile of BMI to carry E40K variant to more than 10-time
Table 2 Linear regression analyses of the association of ANGPTL4 E40K variant and circulating lipid levels
a.
Beta 95%CI p R2
HDL: 0.065 7.16E-05 1.16E-03 0.027 0.003
TG: 0.064 1.46E-04 9.67E-06 0.025 0.003
b.
Beta 95%CI p R2 ΔR2
HDL: sex: 0.345 8.345 11.475 2.4 × 1033 0.119
E40K 0.060 0.621 11.988 0.030 0.122 0.004
TG: age 0.099 0.304 1.119 0.001 0.010
E40K 0.062 96.722 3.968 0.033 0.014 0.004
sex 0.063 27.258 1.109 0.034 0.017 0.004
a. Unadjusted. 95%CI: 95% Confidence Interval. R2: percentage of dependent-variable variation explained by the model.
b. adjusted model for age, sex and BMI. Only significant variables are shown.
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higher compared lower-quartile individuals (OR = 11.886
[1.392–101.504] p = 0.024).
Also, none of E40K carriers with obesity had type 2 di-
abetes. The absence of diabetes, together with the
favourable lipid profile, identifies obese E40K carriers as
similar to the metabolically healthy obese (MHO) patients.
In contrast 38.3% (316/828) of E40E carriers with obesity
had diabetes and/or dyslipidaemia. This difference be-
tween ANGPTL4 E40K carriers and wild-types was highly
significant (p = 0.0106), confirming the plausible protec-
tive effects of ANGPTL4 E40K variant on cardio-
metabolic risk factors.
Summarizing
E40K carriers show significant lower levels of TG and
higher levels of HDLc than non-carriers, both in the
Table 3 Clinical characteristics of obese Italian sub-population (n = 863) stratified for E40K ANGPTL4 variant
Obese population Obese E40E Obese E40K
p-valuen = 863 Median (25–75)% Median (25–75)% Median (25–75)%
Sex M/F (%) 311/552 (36/64) 302/541 (36/64) 9/11 (45/55) -
Age (yrs) 47 (35–58) 47 (35–58) 46.5 (29–60) 0.762
BMI (kg/m2) 39.5 (34.3–46) 39.5 (34–46) 40.3 (36–47) 0.717
G0’ (mg/dl) 94 (84–111) 94 (84–111) 94.5 (84–107) 0.846
G120’ (mg/dl) 122 (100–150) 122 (100–151) 105 (97–139.5) 0.182
INS0’ (μU/mL) 24.1 (15.8–36.5) 24 (15.7–36.2) 29.8 (22–49.9) 0.143
INS120’ (μU/mL) 11.2 (58.4–200) 11.3 (58.4–200) 99.5 (60.5–197) 0.869
Col Tot (mg/dl) 196.4 (172–224) 196.4 (173–224) 196.5 (160–232) 0.854
TG (mg/dl) 119.2 (84.9–170.2) 121 (86–171) 79 (58–111) 0.001
HDLc (mg/dl) 47 (40–55) 47 (40–55) 48 (42–66) 0.235
LDLc (mg/dl) 122.1 (99.4–145.6) 122 (99–146) 128 (97–147) 0.741
HOMA-IR 5.6 (3.5–9.4) 5.5 (3.5–9.4) 7.1 (4.5–11.7) 0.316
HOMA-B 295.6 (184–466) 293.5 (181–465) 391.6 (233–498) 0.183
ISI 2.1 (1.3–3.3) 2.1 (1.3–3.3) 2.1 (1.1–2.7) 0.464
PAS (mmHg) 130 (120–140) 130 (120–140) 130 (120–140) 0.486
PAD (mmHg) 80 (80–90) 80 (80–90) 85 (70–90) 0.947
Data are expressed as median (25th–75th) percentile range, unless for gender expressed as count and percentage. P-value are calculated by
Mann–Whitney.
BMI: Body Mass Index; G0’: Fasting glucose from OGTT; G120’: blood glucose at 120’ after OGTT; INS0’: Fasting Insulin from OGTT; INS120’:
Circulating Insulin at 120’ after OGTT; Col Tot: Total Cholesterol; HDLc: High Density Lipoprotein cholesterol; TG: Triglycerides; LDLc: Low Den-
sity lipoprotein cholesterol; AST: aspartate transaminase; ALT: alanine transaminase; PAS: Pulmonary Artery Pressure Systolic; PAD: Pulmonary
Artery Pressure Diastolic; HOMA-IR: homeostatic model assessment of insulin resistance; HOMA-B: homeostatic model assessment of beta-
cell function; ISI: Matsuda Insulin Sensitive Index.
Figure 1 Comparison of mean lipid levels in Italian obese sub-popu-
lation. a. Triglycerides b. HDLc. P-values are assessed by linear re-
gression. *P values are adjusted for age, gender, BMI and diabetes
status
Figure 2 Percentage of patients with obesity with normal lipid profile
stratified by E40 genotypes. Normal lipid profile was defined as Tri-
glycerides <150 mg/dL and HDLc men >40 women >50 mg/dL
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general population and in the obese sub-cohort. Carriers
of E40K have a high probability (6-fold) of having low
TGs and (10-fold) of having a higher BMI. Also, no sub-
stantial effect of E40K on blood circulating levels of glu-
cose nor insulin was confirmed. Overall, a net
enrichment of E40K carriers in the “non-pathological” ex-
tremes of several traits, such as TG and HDLc levels or
MHO phenotype, was observed.
Discussion
Here it is shown that ANGPTL4 gene E40K carriers have
lower levels of TGs and higher levels of HDLc than non-
carriers, both in the general population and in the obese
sub-cohort. Carriers of E40K have a high probability
(6-fold) of having low TGs and (10-fold) of having a higher
BMI. Also no substantial effect of E40K on circulating
blood levels of glucose or insulin was detected. Further-
more, for the first time, it was observed that in E40K
carriers with obesity, despite the high body weight (per-se
a major risk factor for CVD), the lipid profile is far better
than wild-type ANGPTL4 carriers. This findings confirm
and expand previous observations in the general popula-
tion (1,3,9,15,16), demonstrating that also in participants
with obesity, by definition at more risk for metabolic alter-
ations, ANGPTL4 E40K variant is capable to ameliorate
lipid levels.
Based on recent molecular and cellular research, these
findings fit with the proposed role for ANGPTL4 in lipid
metabolism, controlling circulating TRLs levels and lipid
deposition in storage (AT) and oxidative (heart and mus-
cle) tissues. In particular, the hypothesized effect on adi-
pose tissue, both white and brown (4,16) is exerted
principally by tissue-specific LPL inhibition, thus main-
taining the equilibrium of circulating TRLs during fast
and feeding states, in concert with ANGPTL3 and 8,
which show similar function mainly in muscle tissue,
allowing proper nutrient partitioning. Hence, LoF in
ANGTPL4 may play a role in improving the lipid profile
without the risk of aberrant deposition of lipids in heart,
muscle and liver tissues. Indeed, Aryal et al. observed in
their AT selective ANGPTL4-KO mouse model that
skeletal muscle and hepatic lipid ectopic accumulation
was significantly reduced while adipose tissue uptake of
FFAs was enhanced, by augmenting TG lipolysis and ox-
idation. This leads, in this animal model, to the reduction
of both atherosclerotic plaques and pro-inflammatory
cytokines, together with the reduction of CVD risk. Fur-
thermore, Janssen et al. (8) observed that mice lacking
ANGPTL4 displayed an increase in body weight and
visceral adipose tissue mass through enhanced visceral
adipose tissue lipoprotein lipase activity, without meta-
bolic impairment.
The phenotype of E40K carriers with obesity is there-
fore that of a patient with obesity without significant met-
abolic alterations, similar to the phenotype described as
metabolic healthy obesity (MHO) (22,23). Metabolic
healthy obesity defines a subgroup of individuals with
obesity in which the metabolic abnormalities that com-
monly accompany excess adiposity are absent. However,
the prognostic value of MHO is controversial. The lack of
standard definitions for metabolic health and obesity as
well as the dynamic properties of MHO may have contrib-
uted to these inconsistent results. For example, as
reviewed by Phillips (23), the lack of a universal definition
of metabolic health and differences in obesity classifica-
tion (BMI vs. % body fat) account for a large proportion
of the disparity in MHO prevalence. It follows that the
question whether the subgroup of patients with MHO is
really without an increased risk of major chronic diseases
such as CVD is still open. Recently, in a large follow-up
study of 30 years of women stratified as metabolically
healthy by the absence of hypertension, diabetes and hy-
percholesterolemia, the authors observed that women
with obesity who maintained a metabolically healthy phe-
notype during the follow-up still had an increased risk of
CVD compared with women with a stable normal weight
who were metabolically healthy (24). Similar results were
obtained in the Whitehall II cohort, where MHO patients
had increased mortality risk compared to the metaboli-
cally healthy normal weight participants (25). In this sce-
nario obese ANGPTL4 E40K carriers may represent a
“reference” of a metabolically healthy patients with obe-
sity, and E40K variant in ANGPTL4 can be considered a
genetic marker for this relevant but largely undefined
healthy obese phenotype.
As proposed by recent studies on the effects of un-
common variants (26), an enrichment of carriers E40K
Figure 3 Enrichment of E40K carriers in the extremes of the
quartiles (25th vs 75th) of Triglycerides and BMI in the whole popula-
tion and in the obese sub-population. 25th and 75th limits for TGs
and BMI are shown in table 1 (whole population) and 3 (obese sub-
population)
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variant in one extreme of the associated traits (BMI and
TG) was found. In particular, carriers of E40K were more
frequent in the lower quartile of TG, in the upper quartile
of BMI and in the patient sub-group that showed a normal
lipid profile (i.e. TG ≤150 mg/dL and HDLc ≥40
or ≥ 50 mg/dL, in men and women respectively).
Strength of this work are the number of study
participants, together with the deep characterization of
the obese population. To the best of our knowledge, this
is the first time that this association was assessed in a
large obese cohort. Limitation can be recognized in the
cross-sectional design of this study, and only long-term
follow-up will conclusively confirm these findings.
In conclusion, in this Italian population ANGPTL4
E40K LoF variant is confirmed to lower circulating TG
and enhance HDLc levels. Carriers of E40K have a high
probability (6-fold) of having low TGs and (10-fold) of
having a higher BMI, possibly through lipid deposition
in adipose tissue. No evidence of the effects on circulat-
ing levels of insulin or glucose was observed, suggest-
ing that the molecular mechanism involved in
enhancing the lipid profile, even in the obese sub-
population, is selective on LPL activity in AT. Overall,
the phenotype of E40K carriers with obesity is that of
an individual without significant metabolic alterations, re-
sembling the phenotype described as metabolic healthy
obesity.
From a clinical point of view, persons with obesity that
are carriers of the E40K variant are certainly protected
from lipid alterations. Hence, ANGPTL4 E40K LoF is a ge-
netic marker of a healthier lipid profile in obesity, which
can be used to define individual characteristics towards
a more personalized medicine.
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